Evidence map›Paper›PMID 31585543›Full record

ArticleRadiation oncology (London, England)2019

Prospective intra/inter-observer evaluation of pre-brachytherapy cervical cancer tumor width measured in TRUS and MR imaging.

Mario Federico, Carmen Rosa Hernandez-Socorro, Ivone Ribeiro, Jesus Gonzalez Martin, Maria Dolores Rey-Baltar Oramas, Marta Lloret Saez-Bravo, Pedro Carlos Lara Jimenez

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mario FedericoRadiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain. mariofedericos@yahoo.it.ORCID http://orcid.org/0000-0002-6184-9070
Carmen Rosa Hernandez-SocorroRadiology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Ivone RibeiroRadiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain.
Jesus Gonzalez MartinUnidad de Investigación, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Maria Dolores Rey-Baltar OramasRadiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain.
Marta Lloret Saez-BravoRadiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain.
Pedro Carlos Lara JimenezRadiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain.
Hospital Universitario de Gran Canaria Doctor Negrín · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUltrasound (US) imaging has been proved as an excellent diagnostic tool in gynecology and, due to its wide availability and limited cost, is under intense investigation as base for dose adaptation in cervical cancer brachytherapy. Purpose of this work is to test inter/intra-observer uncertainties between magnetic resonance (MR) and trans-rectal ultrasound (TRUS) imaging in defining maximum tumor width before first brachytherapy (BT) application in a prospective cohort of cervical cancer patients undergoing image-guided adaptive brachytherapy (IGABT).

methodsOne hundred ten consecutive cervical cancer patients treated between 2013 and 2016 were included. Before the first BT implant patients underwent MR and TRUS scan with no applicator in place. Images were independently analyzed by three examiners, blinded to the other's results. With clinical information at hand, maximum tumor width was measured on preBT TRUS and MR. Quantitative agreement analysis was undertaken. Intra-class correlation coefficient (ICC), Passing-Bablok and Bland Altman plots were used to evaluate the intra/inter-observers measurement agreement.

resultsAverage difference between tumor width measured on MR (HRCTV

conclusionsOur results suggest that TRUS is equivalent to MR in assessing preBT tumor maximum width in cervical cancer FIGO stage I/II. In more advanced stages TRUS seems to be slightly inferior to MR although maintaining a good agreement to gold standard imaging.

Indexed as

BrachytherapyObserver VariationAdenocarcinomaAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, Squamous CellFemaleHumansMagnetic Resonance ImagingMiddle AgedPrognosisProspective StudiesUltrasonographyUterine Cervical Neoplasms3D brachytherapyCervical CancerImage guided brachytherapyMagnetic resonanceTRUSUltrasound

Identifiers

PMID31585543
PMCPMC6778388
OpenAlexW2979265757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.